The illness of sch izo p h re n ia, as it is understo od today, appears to co nsis t of a heterogeneous group o f di sorders wh ich sha re several common features, suc h as partial response to medications, poor long-t erm prognosis, a nd th e presen ce of psychotic sym p to ms . These psychotic sym ptoms have bee n arbitraril y d ivided into two subgro ups , positive and negati ve, in a n attem pt to better understand this di sease process ( 1,2). The positi ve sym p to ms, suc h as d elusio ns and hallu cinations, ge nera lly ha ve a n acute o nse t with frequent exacerbations and rem issio ns and a favorable long-t erm p rognosis a nd response to med ica tio ns. T he negati ve sym p to ms , whic h include affec tive blun ting , so cia l wit hdrawal , apa t hy, and an hed o n ia, tend to be chron ic a nd typi call y fa il to respond satisfacto ril y to sta ndard neu roleptics (3) . T his fact has been illustra ted in so me schizophren ic patients b y th e rete ntio n of negat ive sym p toms ev en after trea tm ent a nd subseq uen t re d uc tio n of their posit ive sym p toms. Resea rche rs ha ve co ncl uded th at th e negati ve sym p to ms are mo re refract o r y th an th eir positive co u n terpa rts based upon th is freq ue ntly o bserved phe nome no n (4) .
T h is resista nce has led to a search fo r agents more e ffective than the sta nda rd neu roleptics in re lieving the emotio na l wit hdrawa l, social iso latio n, and a pat hy of t h is " deficit" state . Research wh ich uti lizes such medications as L-d opa , su lpir ide, a nd a lprazolam for th e treatmen t of th ese negative sym p to ms is cu r rently unde r wa y (5). Gould a nd co -worke rs have found t hat members of th e diph en ylbutylpipe ridine group of neu rol eptics, suc h as pimozide, seem to be u niquel y suite d fo r th e treatment of negati ve sch izo p hrenic symptoms. T hese neurol eptics are str uc tu ra lly sim ila r to ve rapa rnil-like d rugs a nd have strong ca lciu m blocking effects wit h in th e ce ntra l nervous system (6). It is this uniqu e effec t upon ca lciu m cha n ne ls that is thought to be resp on sibl e fo r t heir efficacy in relieving th e negative symptoms. Lithium ca r bona te, wh ich a lso sha res sim ilar it ies to verapamil in th at it alte rs ca lciu m metaboli sm , blocks d epolarization , a nd co m petes with ca lciu m ions within th e neur o muscula r ce lls, has been useful in treating th e negati ve sym ptoms of sch izo p hrenia as well (7) . Verapamil itsel f has been used successfully as a replacement fo r lith iu m carbonat e in th e (8 ,9) . It has also been used in prelimina r y studies to treat acute exace r bat io ns of schizophrenia (10) , but its usefuln ess in treating th e negative sym p to ms of schizophrenia ha s ye t to be exp lored . We report a ca se o f a sch izop h ren ic patient with prominent negative sym p to ms, pre viously resistant to treatment with the standard neuroleptics, that responded to verapam il.
CASE REPORT
The patient, a 36-yea r-o ld white male, was fir st seen becau se of his bizarre behavior and persistent auditory hallucinations. T he patient was livin g in a group home at the tim e , and had been refusing to leave hi s bedroo m closet because th e vo ices in his head told him to stay in th e closet. O verall , he was socia lly withdrawn and noncommunicati ve fo r mo st of th e t im e . He felt anergic a nd found it diffi cult to get involved in th e ac t ivit ies at th e group ho me . His affect was flat with little variation. He d enied feeling d epressed and did not exhibit an y disorder of his sleep or appetite. H e first sta rt ed havin g psych iatr ic problems at th e ag e of 18, wh en he was ho spitali zed fo r psycho t ic be havior. Sin ce th en he had had four ot her ho spitali zations and had bee n on various neuroleptics, as well as short trials o f lithium carbonat e , oxazepam, and amitriptylin e. At th e present time, he was receiving thi othixen e 40 mg/ d ay and trih ex yphenidyl h ydrochloride 2 mg twice daily. For th e mo st part, his hall ucinations, delusions, and o ther positi ve sym p to m s resp onded we ll to med ications, however, he had a lways been withdrawn , lacked th e moti vation to do things, and showed very little e mo t io n at all. Because of hi s partial response to neurol eptics in th e past , it was decided that th e patient be included in an ongoing research project th at was in vest igatin g th e use of ve ra pa m il, a ca lciu m cha n nel block er, to treat th e negative sym p to ms o f schizophrenia. The patient was told th at he would rece ive eit he r ve ra pa m il, haloperidol , o r pla cebo durin g t he co u rse of t he st udy, and co uld withdraw at a ny tim e and co n t in ue to recei ve treatm ent. He signed informed consent form s at this tim e.
A complete ph ysical exa m inat io n as we ll as a n electroca rd iogram , an e lec troencep ha logra m, and routine laborato r y tests suc h as co mplete blood count with differential , se ru m e lec trolytes, g lucose, RPR , and live r and th yroid fun cti ons we re all normal. The patient was ini tiall y sta r te d o n halope ri d o l and th e dose was gradually increased to 20 mg/day a fte r two week s. At t h is time he state d that th e auditory hallucinations had become less bothersome and he no longer resp onded to th eir commands. H e con t in ue d , h o we ve r , to be sociall y withdrawn a nd a ne rgic, exh ibiting ma rk ed a n hedon ia and bl u nti ng of affect. After six week s of treatment with haloperidol , 30 m g/day, he showed no furth er improvem ent. Pla cebo was started at this tim e, but after fou r wee ks he was on ce aga in responding to his auditory hallucinations. The placeb o was d iscon t inued a nd ve ra pam il was sta r ted at a dose o f 80 mg tw ice d a ily. T he verapamil was grad ua lly increased to 3 20 mg/day by th e second wee k. U pon eva luation , th e patient reported an absence of auditory hallucinations a nd he se emed some wh a t brighter and more talkative. Over the next fou r weeks he was no ted to be mor e active on th e unit and he e x h ib ite d a great er range o f affect. In fact , at on e po int he was found playing a joke on se ve ra l sta ff members. The pa tien t to lera ted the haloperidol, placebo, and ve rap a m il well , noting o n ly so m e in itial sedation with the haloperidol and dizziness with the ve rapamil. These side e ffec ts passed quickly, and weekl y vital signs, as well as bi-monthl y e lec troca r diogram s, were a ll unremarkable. The patient was dis charged on verapamil80 m g fou r t im es da ily, and he has continued to do well for th e last six months.
CO NC LU SIO N
Although this is onl y a single ca se report, the ev idence suggests tha t verapamil can b e effective in th e treatment of schizoph renia. More specifica lly, verapamil seemed to be especi all y useful in reducing this pa t ie n t 's nega tive sym p to ms, which in th e past had been r esistant to treatme nt wit h th e sta ndard neuroleptics. Single case r eports n eed to be weighed accordin gl y, bu t o ne shou ld be aw are that single cas e reports in th e pa st, suc h as th ose invo lving alpr a zol a m or L-dopa in the treatment of sc h izop h re n ia ( 1 1, 12), ha ve p roven to be t he gatew a y for furth er inv estigation and success in th e man agement a nd improvement of negative schizophrenic sym p to ms. The resu lts of t h is case at least suggest th e need for further research on th e use o f verapa m il a nd other ca lcium cha n ne l blockers to treat th e negative symptoms o f sch izo p h ren ia .
